Literature DB >> 8281668

Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat.

S E Litwin1, S E Katz, J P Morgan, P S Douglas.   

Abstract

BACKGROUND: The development of heart failure after acute myocardial infarction (MI) may be related to alterations of left ventricular (LV) structure and function. Pathological LV remodeling may exacerbate systolic and diastolic dysfunction because increased cavity dimensions tend to increase LV wall stress. Unfortunately, many complicating factors have made it difficult to clearly define the time course of LV remodeling after myocardial infarction in patients, and the contribution of structural changes to altered function has not been fully explored. METHODS AND
RESULTS: To determine the type, magnitude, and time course of changes in LV geometry and function, we performed transthoracic Doppler echocardiographic examinations in rats before and 1 and 6 weeks after transmural MI induced by coronary ligation. LV internal diastolic dimension was greater in infarcted than in sham-operated rats at 1 and 6 weeks after MI (9.4 +/- 0.6 versus 8.0 +/- 0.5 and 10.1 +/- 0.9 versus 8.5 +/- 0.9 mm, respectively; P < .05 compared with sham-operated rats). There was significant thinning of the infarcted anterior wall at 1 and 6 weeks (0.99 +/- 0.2 versus 1.33 +/- 0.19 and 0.96 +/- 0.22 versus 1.51 +/- 0.18 mm, P < .05), while the thickness of the noninfarcted posterior wall increased but was not different from normal growth in sham-operated rats. Six weeks after surgery, fractional shortening was impaired (11 +/- 5% versus 35 +/- 5%, P < .05), and systolic thickening of the noninfarcted posterior wall was depressed (38 +/- 9% versus 67 +/- 18%, P < .05) in infarcted rats compared with shams. These changes in structure and systolic function were accompanied by progressive alterations in LV diastolic filling. Peak early filling velocity increased at 1 and 6 weeks in MI rats (91 +/- 9 versus 79 +/- 9 and 100 +/- 14 versus 74 +/- 11 cm/s, P < .05), and the deceleration rate of the early filling wave was more rapid in rats with MI (21.6 +/- 5.0 versus 15.6 +/- 3.1 and 26.1 +/- 9.8 versus 11.2 +/- 2.7 m/s2, P < .05). Late filling velocity was decreased (16 +/- 15 versus 33 +/- 7 and 15 +/- 18 versus 34 +/- 5 cm/s, P < .05), resulting in a marked increase in the ratio of early to late filling. The peak velocity and the velocity-time integral of LV outflow did not change after MI.
CONCLUSIONS: Postinfarction LV remodeling in the rat is characterized by progressive cavity dilatation, inadequate hypertrophy of the surviving myocardium, the gradual development of regional contractile dysfunction in noninfarcted segments, and marked abnormalities of diastolic filling. These changes can be tracked longitudinally with transthoracic echocardiography.

Entities:  

Mesh:

Year:  1994        PMID: 8281668     DOI: 10.1161/01.cir.89.1.345

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  58 in total

1.  Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

Authors:  Anthony Allan; Andrew Fenning; Scott Levick; Andrew Hoey; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction.

Authors:  Shin-ichiro Ueda; Sho-ichi Yamagishi; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Effects of Tongguan Capsule on post-myocardial infarction ventricular remodeling and cardiac function in rats.

Authors:  Bo-jun Chen; Jing-xi Feng; Xue-xu Su; Li-qin Meng; Zhi-shang Li; Yan-li Gao; Xiao-li Xia
Journal:  Chin J Integr Med       Date:  2010-05-16       Impact factor: 1.978

4.  Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure.

Authors:  S E Litwin; S E Katz; J P Morgan; P S Douglas
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Age-associated alterations of cardiac structure and function in the female F344xBN rat heart.

Authors:  Jacqueline Fannin; Kevin M Rice; Srininvas Thulluri; Lucy Dornon; Ravi Kumar Arvapalli; Paulette Wehner; Eric R Blough
Journal:  Age (Dordr)       Date:  2014-07-27

6.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury.

Authors:  Keiichi Hishikari; Jun-ichi Suzuki; Masahito Ogawa; Kazuya Isobe; Teisuke Takahashi; Michihito Onishi; Kiyoshi Takayama; Mitsuaki Isobe
Journal:  Cardiovasc Res       Date:  2008-09-18       Impact factor: 10.787

7.  Protective effects of Jiashen Prescription () on myocardial infarction in rats.

Authors:  Ming-Jun Zhu; You-Ping Wang; Shi-Yang Xie; Wei-Hong Liu; Bin Li; Yong-Xia Wang; He Wang; Bo-Li Zhang
Journal:  Chin J Integr Med       Date:  2014-05-10       Impact factor: 1.978

8.  Activation of CaMKIIδA promotes Ca2+ leak from the sarcoplasmic reticulum in cardiomyocytes of chronic heart failure rats.

Authors:  Le Gui; Xin Guo; Zhe Zhang; Hui Xu; Ya-Wei Ji; Ren-Jun Wang; Jiang-Hua Zhu; Qing-Hui Chen
Journal:  Acta Pharmacol Sin       Date:  2018-06-14       Impact factor: 6.150

9.  Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction.

Authors:  Shirley S Mihardja; Dongwei Gao; Richard E Sievers; Qizhi Fang; Jinjin Feng; Jianming Wang; Henry F Vanbrocklin; James W Larrick; Manley Huang; Michael Dae; Randall J Lee
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

10.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

Authors:  Que Liu; Christen Anderson; Anatoly Broyde; Clara Polizzi; Rayne Fernandez; Alain Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-16       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.